Q6, a novel hypoxia-targeted drug, regulates hypoxia-inducible factor signaling via an autophagy-dependent mechanism in hepatocellular carcinoma

Autophagy

Volumn 10, Issue 1, 2014, Pages 111-122

  Liu, Xiao Wen ^a   Cai, Tian Yu ^a   Zhu, Hong ^a   Cao, Ji ^a   Su, Yi ^a   Hu, Yong Zhou ^b   He, Qiao Jun ^a   Yang, Bo ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Autophagy; Dual modulation mechanisms; Hypoxia activated prodrug; Posttranslational regulation; Targeting treatment

Indexed keywords

AUTOPHAGY; DUAL MODULATION MECHANISMS; HYPOXIA-ACTIVATED PRODRUG; POSTTRANSLATIONAL REGULATION; TARGETING TREATMENT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CARCINOMA, HEPATOCELLULAR; CASPASES; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS; LYSOSOMES; MICE; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; PROTEOLYSIS; QUINOXALINES; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84894414818     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.4161/auto.26838     Document Type: Article

References (30)

1. American Cancer Society. Cancer Facts & Figures 2010. Atlanta, GA: American Cancer Society; 2010
2. Lee YH, Andersen JB, Song HT, Judge AD, Seo D, Ishikawa T, Marquardt JU, Kitade M, Durkin ME, Raggi C, et al. Definition of ubiquitination modulator COP1 as a novel therapeutic target in human hepatocellular carcinoma. Cancer Res 2010; 70:8264-9; PMID:20959491; http://dx.doi.org/10.1158/0008-5472.CAN-10-0749
3. Yopp AC, Schwartz LH, Kemeny N, Gultekin DH, Gonen M, Bamboat Z, Shia J, Haviland D, D'Angelica MI, Fong Y, et al. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. Ann Surg Oncol 2011; 18:2192-9; PMID:21286939; http://dx.doi.org/10.1245/s10434-011-1570- 1
4. Matsumoto S, Yasui H, Mitchell JB, Krishna MC. Imaging cycling tumor hypoxia. Cancer Res 2010; 70:10019-23; PMID:21159626; http://dx.doi.org/10.1158/ 0008-5472.CAN-10-2821
5. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721-32; PMID:13130303; http://dx.doi.org/10.1038/nrc1187 (Pubitemid 37328811)
6. Nath B, Szabo G. Hypoxia and hypoxia inducible factors: diverse roles in liver diseases. Hepatology 2012; 55:622-33; PMID:22120903; http://dx.doi.org/10. 1002/hep.25497
7. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004; 4:43747; PMID:15170446; http://dx.doi.org/10.1038/nrc1367
8. Melillo G. Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev 2007; 26:34152; PMID:17415529; http://dx.doi.org/10.1007/s10555- 007-9059-X
9. Moradpour D, Blum HE. Pathogenesis of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2005; 17:477-83; PMID:15827436; http://dx.doi.org/10.1097/ 00042737-200505000-00002 (Pubitemid 40592703)
10. Finger EC, Giaccia AJ. Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev 2010; 29:28593; PMID:20393783; http://dx.doi.org/10.1007/s10555-010-9224-5
11. Poon E, Harris AL, Ashcroft M. Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev Mol Med 2009; 11:e26; PMID:19709449; http://dx.doi.org/10.1017/S1462399409001173
12. Manalo DJ, Rowan A, Lavoie T, Natarajan L, Kelly BD, Ye SQ, Garcia JG, Semenza GL. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 2005; 105:659-69; PMID:15374877; http://dx.doi.org/10. 1182/blood-2004-07-2958 (Pubitemid 40070750)
13. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, et al. Targeting of HIFalpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292:468-72; PMID:11292861; http://dx.doi.org/10. 1126/science.1059796 (Pubitemid 32335942)
14. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012; 33:207-14; PMID:22398146; http://dx.doi.org/10.1016/j.tips.2012.01.005
15. Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. Nat Rev Drug Discov 2003; 2:803-11; PMID:14526383; http://dx.doi.org/10.1038/ nrd1199 (Pubitemid 37361812)
16. Hu Y, Xia Q, Shangguan S, Liu X, Hu Y, Sheng R. Synthesis and biological evaluation of 3-arylquinoxaline2-carbonitrile 1,4-di-N-oxide derivatives as hypoxic selective anti-tumor agents. Molecules 2012; 17:9683-96; PMID:22890172; http://dx.doi.org/10.3390/molecules17089683
17. Xiang ZL, Zeng ZC, Fan J, Tang ZY, Zeng HY, Gao DM. Gene expression profiling of fixed tissues identified hypoxia-inducible factor-1a, VEGF, and matrix metalloproteinase-2 as biomarkers of lymph node metastasis in hepatocellular carcinoma. Clin Cancer Res 2011; 17:5463-72; PMID:21712445; http://dx.doi.org/10.1158/1078-0432.CCR-10-3096
18. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 1998; 28:68-77; PMID:9657098; http://dx.doi.org/10.1002/ hep.510280111 (Pubitemid 28299987)
19. Koh MY, Powis G. Passing the baton: the HIF switch. Trends Biochem Sci 2012; 37:364-72; PMID:22818162; http://dx.doi.org/10.1016/j.tibs.2012.06.004
20. Levine B. Cell biology: autophagy and cancer. Nature 2007; 446:745-7; PMID:17429391; http://dx.doi.org/10.1038/446745a (Pubitemid 46582063)
21. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science 2000; 290:1717-21; PMID:11099404; http://dx.doi.org/10. 1126/science.290.5497.1717 (Pubitemid 32004796)
22. Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, Timmer W, DiPaola RS, Lotze MT, White E. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 2011; 17:654-66; PMID:21325294; http://dx.doi.org/10.1158/1078-0432.CCR-10-2634
23. Asghar U, Meyer T. Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? J Hepatol 2012; 56:686-95; PMID:21971559; http://dx.doi.org/10.1016/j.jhep.2011.07.031
24. Hicks KO, Siim BG, Jaiswal JK, Pruijn FB, Fraser AM, Patel R, Hogg A, Liyanage HD, Dorie MJ, Brown JM, et al. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clin Cancer Res 2010; 16:4946-57; PMID:20732963; http://dx.doi.org/10.1158/1078-0432.CCR-10-1439
25. Liu Q, Sun JD, Wang J, Ahluwalia D, Baker AF, Cranmer LD, Ferraro D, Wang Y, Duan JX, Ammons WS, et al. TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. Cancer Chemother Pharmacol 2012; 69:1487-98; PMID:22382881; http://dx.doi.org/10.1007/s00280-012-1852-8
26. Takamura A, Komatsu M, Hara T, Sakamoto A, Kishi C, Waguri S, Eishi Y, Hino O, Tanaka K, Mizushima N. Autophagy-deficient mice develop multiple liver tumors. Genes Dev 2011; 25:795800; PMID:21498569; http://dx.doi.org/10.1101/gad. 2016211
27. Wang Z, Cao L, Kang R, Yang M, Liu L, Zhao Y, Yu Y, Xie M, Yin X, Livesey KM, et al. Autophagy regulates myeloid cell differentiation by p62/SQSTM1mediated degradation of PML-RARa oncoprotein. Autophagy 2011; 7:401-11; PMID:21187718; http://dx.doi.org/10.4161/auto.7.4.14397
28. Zhang H, Bosch-Marce M, Shimoda LA, Tan YS, Baek JH, Wesley JB, Gonzalez FJ, Semenza GL. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem 2008; 283:10892-903; PMID:18281291; http://dx.doi.org/10.1074/jbc.M800102200
29. Wilkinson S, O'Prey J, Fricker M, Ryan KM. Hypoxia-selective macroautophagy and cell survival signaled by autocrine PDGFR activity. Genes Dev 2009; 23:1283-8; PMID:19487569; http://dx.doi.org/10.1101/gad.521709
30. Bjorkoy G, Lamark T, Brech A, Outzen H, Perander M, Overvatn A, Stenmark H, Johansen T. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtininduced cell death. J Cell Biol 2005; 171:603-14; PMID:16286508; http://dx.doi.org/10.1083/jcb.200507002 (Pubitemid 41668720)